Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 14/20 | 0.83 |
| ▸ | OPRD1 | P41143 | 14/20 | 0.83 |
| ▸ | OPRK1 | P41145 | 11/20 | 0.77 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.77 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.77 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14653018 | 1.00 | OPRM1 (0.83) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| SCHEMBL3765655 | 1.00 | OPRM1 (0.83) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| SCHEMBL14653019 | 1.00 | OPRM1 (0.83) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| SCHEMBL16449953 | 1.00 | OPRM1 (0.83) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| SCHEMBL14993654 | 1.00 | OPRM1 (0.83) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Hydrochloric Acid SCHEMBL28411127 | 0.99 | OPRM1 (0.81) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Hydrochloric Acid SCHEMBL6271554 | 0.99 | OPRM1 (0.81) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| Hydrochloric Acid SCHEMBL6271253 | 0.99 | OPRM1 (0.81) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| SCHEMBL8784947 | 0.92 | OPRM1 (0.81) | OPRM1OPRD1OPRK1KCNE1KCNQ1 | |
| SCHEMBL8784951 | 0.92 | OPRM1 (0.81) | OPRM1OPRD1OPRK1KCNE1KCNQ1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150150819-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2015-06-04 | — | — | US | disclosed |
| US-20150045556-A1 | PROCESSES FOR THE PREPARATION OF PERIPHERAL OPIOID ANTAGONIST COMPOUNDS AND INTERMEDIATES THERETO | DOLLE ROLAND E (US) | 2015-02-12 | — | — | US | disclosed |
| US-20150045556-A1 | PROCESSES FOR THE PREPARATION OF PERIPHERAL OPIOID ANTAGONIST COMPOUNDS AND INTERMEDIATES THERETO | DOLLE ROLAND E (US) | 2015-02-12 | — | — | US | disclosed |
| US-20140303211-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | MERCK SHARP & DOHME CORP. | 2014-10-09 | — | — | US | disclosed |
| US-20140057947-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | ADOLOR CORPORATION (US) | 2014-02-27 | — | — | US | disclosed |
| WO-2013080221-A2 | PROCESS FOR ALVIMOPAN | HETERO RESEARCH FOUNDATION (IN) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013080221-A2 | PROCESS FOR ALVIMOPAN | HETERO RESEARCH FOUNDATION (IN) | 2013-06-06 | — | — | WO | disclosed |
| US-8404693-B2 | Substituted piperidine compounds and methods of their use | ADOLOR CORPORATION (US) | 2013-03-26 | — | — | US | disclosed |
| WO-2013012871-A1 | PROCESSES FOR THE PREPARATION OF PERIPHERAL OPIOID ANTAGONIST COMPOUNDS AND INTERMEDIATES THERETO | ADOLOR CORPORATION (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20120232114-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | ADOLOR CORPORATION (US) | 2012-09-13 | — | — | US | disclosed |
| WO-2010144446-A1 | (S) -2-BENZYL-3- ( (3R, 4R) -4- (3 -CARBAMO YLPHENYL) -3, 4-DIMETHYLPIPERIDINYL) PROPANOIC ACID AND SALT THEROF AS ANTAGONISTS OF THE OPIOID RECEPTORS | ADOLOR CORPORATION (US) | 2010-12-16 | — | — | WO | disclosed |
| WO-2010144446-A1 | (S) -2-BENZYL-3- ( (3R, 4R) -4- (3 -CARBAMO YLPHENYL) -3, 4-DIMETHYLPIPERIDINYL) PROPANOIC ACID AND SALT THEROF AS ANTAGONISTS OF THE OPIOID RECEPTORS | ADOLOR CORPORATION (US) | 2010-12-16 | — | — | WO | disclosed |
| US-20100311782-A1 | SUBSTITUTED PIPERIDINYLPROPANOIC ACID COMPOUNDS AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311782-A1 | SUBSTITUTED PIPERIDINYLPROPANOIC ACID COMPOUNDS AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100311782-A1 | SUBSTITUTED PIPERIDINYLPROPANOIC ACID COMPOUNDS AND METHODS OF THEIR USE | ADOLOR CORPORATION (US) | 2010-12-09 | — | — | US | disclosed |
| US-20100240690-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | ADOLOR CORPORATION (US) | 2010-09-23 | — | — | US | disclosed |
| US-7700626-B2 | Such as alvimopan and active metabolite, with improved solubility and bioavailability for oral or parenteral administration, injectable dosage formulations, kits; lyophilization; vacuum drying; storage stability | ADOLOR CORPORATION (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090076082-A1 | DEUTERIUM-ENRICHED ALVIMOPAN | PROTIA, LLC (US) | 2009-03-19 | — | — | US | disclosed |
| US-20070092576-A1 | Micronizing with sugar excipient; stability and bioavailability; e.g. alvimopam; solid dosage forms | ADOLOR CORPORATION (US) | 2007-04-26 | — | — | US | disclosed |
| US-20070082053-A1 | Solid dispersions of opioid antagonists | ADOLOR CORPORATION (US) | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140057947-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | OPRK1, OPRL1, OPRM1 | OPRM1 3/4885OPRD1 4/4885OPRK1 1/4885 |
| US-20150045556-A1 | PROCESSES FOR THE PREPARATION OF PERIPHERAL OPIOID ANTAGONIST COMPOUNDS AND INTERMEDIATES THERETO | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885 |
| US-20070082053-A1 | Solid dispersions of opioid antagonists | OPRK1, OPRD1, OPRM1 | OPRM1 3/4885OPRD1 2/4885OPRK1 1/4885 |
| US-20070092576-A1 | Micronizing with sugar excipient; stability and bioavailability; e.g. alvimopam; solid dosage forms | OPRM1, OPRK1, OGFR | OPRM1 1/4885OPRD1 5/4885OPRK1 2/4885 |
| US-20140303211-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | OPRK1, OPRL1, OPRM1 | OPRM1 3/4885OPRD1 4/4885OPRK1 1/4885 |
| US-20090076082-A1 | DEUTERIUM-ENRICHED ALVIMOPAN | LPXN, AVPR2, AVPR1A | OPRM1 205/4885OPRD1 12/4885OPRK1 29/4885 |
| US-20100240690-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | OPRK1, OPRL1, OPRM1 | OPRM1 3/4885OPRD1 4/4885OPRK1 1/4885 |
| US-20150150819-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | OPRK1, OPRM1, OPRD1 | OPRM1 2/4885OPRD1 3/4885OPRK1 1/4885 |
| US-20100311782-A1 | SUBSTITUTED PIPERIDINYLPROPANOIC ACID COMPOUNDS AND METHODS OF THEIR USE | OPRK1, OPRM1, OPRL1 | OPRM1 2/4885OPRD1 4/4885OPRK1 1/4885 |
| US-20120232114-A1 | COMPOSITIONS CONTAINING OPIOID ANTAGONISTS | OPRK1, OPRL1, OPRM1 | OPRM1 3/4885OPRD1 4/4885OPRK1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.